Latest news with #ManagementReport
Hamilton Spectator
14 hours ago
- Business
- Hamilton Spectator
Endeavour Reports Strong H1-2025 Results
NEWS RELEASE – LSE & TSX: EDV All amounts in US$ ENDEAVOUR REPORTS STRONG H1-2025 RESULTS H1 production of 647koz at AISC of $1,281/oz • H1 Free Cash Flow of $514m • Record dividend of $150m London, 31 July 2025 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) ('Endeavour', the 'Group' or the 'Company') is pleased to announce its operating and financial results for Q2-2025 and H1-2025, with highlights provided in Table 1 below. Table 1: Operating and financial highlights from continuing operations 1 1 Continuing Operations excludes the settlement of historic liabilities under the original sale agreement of the Boungou mine. 2 This is a non-GAAP measure, refer to the non-GAAP Measures section for further details. 3 Realised gold prices are inclusive of the Sabodala-Massawa stream and the realised gains/losses from the Group's revenue protection programme . 4 From all operations; calculated as Operating Cash Flow less Cash used in investing activities. 5 Last Twelve Months ('LTM') Trailing EBITDA adj includes EBITDA generated by discontinued operations. Management will host a conference call and webcast today, 31 July 2025, at 8:30 am EST / 1:30 pm BST. For instructions on how to participate, please refer to the conference call and webcast section at the end of the news release. Copies of the Management Report and Financial Statements have been submitted to the National Storage Mechanism and will be filed on SEDAR+. The documents will shortly be available for inspection on the Company's website and at: . Ian Cockerill, Chief Executive Officer, commented: 'Q2-2025 has been another strong quarter for Endeavour, capping an excellent first half of 2025 with 647koz of gold produced at an AISC of $1,281 per ounce; ensuring we are firmly on track to achieve our full-year guidance. As a result of our larger portfolio, following the completion of our growth phase 12 months ago, H1-2025 production was 38% higher than the same period last year, with our all-in sustaining margin 80% higher, ensuring that we realised the full benefit of the strong gold price environment. Over the past 12 months, we have generated $879 million of free cash flow, equivalent to over $687 for every ounce of gold we produced, or a yield of more than 17% from the start of the period. During H1, despite paying approximately 70% of our full-year's taxes, we still generated record free cash flow of $514 million, equivalent to $794 for every ounce of gold we produced, and we are well positioned to continue delivering strong free cash flow in the second half of the year. Underpinned by this strong free cash flow, we have maintained leverage well below our target and declared another record dividend of $150 million for H1-2025, which we have further supplemented with $69 million of share buybacks, equivalent to returns of $338 for every ounce of gold produced for the period. Since our first payments in 2021, we have returned $1.4 billion to shareholders, over 80% above our minimum commitment, and equivalent to $213 for every ounce produced over the period. Looking ahead, the DFS for our tier 1 Assafou project is on schedule for completion by early-2026, and the permitting process is well advanced. Simultaneously, we are continuing to explore the property and expect to outline a resource update later this year, incorporating resources from satellite discoveries in close proximity to Assafou. We are very pleased with the operational performance we have delivered from our expanded portfolio and our ability to convert that performance into cash flow. Our high-margin, long-life operations, coupled with our exciting organic growth pipeline positions us well to continue delivering against our strategic objectives .' OPERATING SUMMARY Table 2: Group Production 1 Includes pre-commercial ounces that are not included in the calculation of All-In Sustaining Costs. Table 3: Consolidated Total Cash Costs 1 This is a non-GAAP measure, refer to the non-GAAP Measures section for further details. 2 Excludes pre-commercial costs associated with ounces from the BIOX expansion project. Table 4: Group All-In Sustaining Costs 1 This is a non-GAAP measure, refer to the non-GAAP Measures section for further details. 2 Excludes pre-commercial costs associated with ounces from the BIOX expansion project. Table 5: AISC Guidance Reconciliation 1 1 Reconciliation illustrates the impact of higher royalty rates as a result of a higher gold price versus $2,000/oz guided gold price for Q2-2025 and H1-2025 of $3,302/oz and $3,107/oz are exclusive of the impact of the revenue protection programme , respectively. FY-2025 OUTLOOK Table 6: FY-2025 Production Outlook 1 1 FY-2025 Production Guidance excludes the impact of the initiatives from the Sabodala-Massawa technical review. Table 7: FY-2025 AISC Outlook 1 1 FY-2025 AISC Guidance is based on an assumed average gold price of $2,000/oz and USD:EUR foreign exchange rate of 0.90. Table 8: FY-2025 Sustaining & Non-Sustaining Capital Expenditure SHAREHOLDER RETURNS PROGRAMME Table 9: Cumulative Shareholder Returns CASH FLOW SUMMARY The table below presents the cash flow and net debt position for Endeavour for the three-month periods ended 30 June 2025, 31 March 2025, and 30 June 2024, with accompanying explanations below. Table 10: Cash Flow and Net Debt 1 Free cash flow, net debt, and adjusted EBITDA are Non-GAAP measures. Refer to the non-GAAP measure section in this press release and in the Management Report. 2 From all operations; calculated as Operating Cash Flow less Cash used in investing activities. 3 Cash and cash equivalents are net of bank overdrafts (nil at 30 June 2025; nil at 31 March 2025; $13.1 million at 31 December 2024; $21.1 million at 30 June 2024; nil at 31 March 2024; nil at 31 December 2023). 4 Trailing twelve month adjusted EBITDA includes EBITDA generated by discontinued operations. 5 Continuing operations excludes the settlement of historic liabilities under the original sale agreement of the Boungou mine. NOTES: Table 11: Tax Payments 1 Included in the 'Other' category is income and withholding taxes paid by Corporate and Exploration entities. EARNINGS FROM CONTINUING OPERATIONS The table below presents the earnings and adjusted earnings for Endeavour for the three-month periods ended 30 June 2025, 31 March 2025, and 30 June 2024, with accompanying explanations below. Table 12: Earnings from operations NOTES: SUMMARISED STATEMENT OF FINANCIAL POSITION The following tables present the summarised statement of financial position for the Group as at 30 June 2025, 31 March 2025, and 31 December 2024, with accompanying explanations below. Table 13: Summarised Statement of Financial Position Table 14: Net Debt and Leverage Ratio 1 Net debt, Adjusted EBITDA, and cash flow per share are Non-GAAP measures. Refer to the non-GAAP measure section in this press release and in the Management Report. 2 Last Twelve Months ('LTM') Trailing Adjusted EBITDA includes EBITDA generated by discounted operations. OPERATING ACTIVITIES BY MINE Houndé Gold Mine, Burkina Faso Table 15: Houndé Performance Indicators Q2-2025 vs Q1-2025 Insights H1-2025 vs H1-2024 Insights FY-2025 Outlook Ity Gold Mine, Côte d'Ivoire Table 16: Ity Performance Indicators Q2-2025 vs Q1-2025 Insights H1-2025 vs H1-2024 Insights FY-2025 Outlook Mana Gold Mine, Burkina Faso Table 17: Mana Performance Indicators Q2-2025 vs Q1-2025 Insights H1-2025 vs H1-2024 Insights FY-2025 Outlook Sabodala-Massawa Gold Mine, Senegal Table 18: Sabodala-Massawa Performance Indicators 1 All-in Sustaining Cost excludes costs and ounces sold related to pre-commercial production at the Sabodala-Massawa BIOX Expansion. Q2-2025 vs Q1-2025 Insights H1-2025 vs H1-2024 Insights FY-2025 Outlook Sabodala-Massawa Technical Review 1a) BIOX throughput: targeting a 15% increase through de-bottlenecking milling, gravity and floatation circuits. 1b) BIOX recoveries: targeting long-term recovery rates of approximately 85% through increased fresh refractory ore mining coupled with increased utilisation of the floatation tails underflow and gravity circuit optimisation. 2) Increasing CIL grade - targeting +1.5g/t non-refractory ores through accelerating high grade underground development and exploration for higher-grade deposits Lafigué Mine, Côte d'Ivoire Table 19: Lafigué Performance Indicators Q2-2025 vs Q1-2025 Insights FY-2025 Outlook Assafou Project, Côte d'Ivoire EXPLORATION ACTIVITIES Table 20: Quarterly Exploration Expenditure and FY-2025 Guidance 1 1 Exploration expenditures include expensed and capitalised exploration expenditures. Houndé mine Ity mine Mana mine Sabodala-Massawa mine Lafigué mine Assafou Project New Ventures and greenfield Exploration CONFERENCE CALL AND LIVE WEBCAST Management will host a conference call and webcast on Thursday 31 July at 8:30 am EDT / 1:30 pm BST to discuss the Company's financial results. The conference call and webcast are scheduled at: 5:30am in Vancouver 8:30am in Toronto and New York 1:30pm in London 8:30pm in Hong Kong and Perth The video webcast can be accessed through the following link: To download a calendar reminder for the webcast, visit the events page of our website here . Analysts and investors are also invited to participate and ask questions by registering for the conference call dial-in via the following link: The conference call and webcast will be available for playback on Endeavour's website . QUALIFIED PERSONS Brad Rathman, Vice President - Operations of Endeavour Mining plc., a Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), is a 'Qualified Person' as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects ('NI 43-101') and has reviewed and approved the technical information in this news release. CONTACT INFORMATION ABOUT ENDEAVOUR MINING PLC Endeavour Mining is one of the world's senior gold producers and the largest in West Africa, with operating assets across Senegal, Côte d'Ivoire and Burkina Faso and a strong portfolio of advanced development projects and exploration assets in the highly prospective Birimian Greenstone Belt across West Africa. A member of the World Gold Council, Endeavour is committed to the principles of responsible mining and delivering meaningful value to people and society. Endeavour is admitted to listing and to trading on the London Stock Exchange and the Toronto Stock Exchange, under the symbol EDV. For more information, please visit . CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION This document contains 'forward-looking statements' within the meaning of applicable securities laws. All statements, other than statements of historical fact, are 'forward-looking statements', including but not limited to, statements with respect to Endeavour's plans and operating performance, the estimation of mineral reserves and resources, the timing and amount of estimated future production, costs of future production, future capital expenditures, the success of exploration activities, the anticipated timing for the payment of a shareholder dividend and statements with respect to future dividends payable to the Company's shareholders, the completion of studies, mine life and any potential extensions, the future price of gold and the share buyback programme. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as 'expects', 'expected', 'budgeted', 'forecasts', 'anticipates', 'believes', 'plan', 'target', 'opportunities', 'objective', 'assume', 'intention', 'goal', 'continue', 'estimate', 'potential', 'strategy', 'future', 'aim', 'may', 'will', 'can', 'could', 'would' and similar expressions. Forward-looking statements, while based on management's reasonable estimates, projections and assumptions at the date the statements are made, are subject to risks and uncertainties that may cause actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the successful completion of divestitures; risks related to international operations; risks related to general economic conditions and the impact of credit availability on the timing of cash flows and the values of assets and liabilities based on projected future cash flows; Endeavour's financial results, cash flows and future prospects being consistent with Endeavour expectations in amounts sufficient to permit sustained dividend payments; the completion of studies on the timelines currently expected, and the results of those studies being consistent with Endeavour's current expectations; actual results of current exploration activities; production and cost of sales forecasts for Endeavour meeting expectations; unanticipated reclamation expenses; changes in project parameters as plans continue to be refined; fluctuations in prices of metals including gold; fluctuations in foreign currency exchange rates; increases in market prices of mining consumables; possible variations in ore reserves, grade or recovery rates; failure of plant, equipment or processes to operate as anticipated; extreme weather events, natural disasters, supply disruptions, power disruptions, accidents, pit wall slides, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; delays in the completion of development or construction activities; changes in national and local government legislation, regulation of mining operations, tax rules and regulations and changes in the administration of laws, policies and practices in the jurisdictions in which Endeavour operates; disputes, litigation, regulatory proceedings and audits; adverse political and economic developments in countries in which Endeavour operates, including but not limited to acts of war, terrorism, sabotage, civil disturbances, non-renewal of key licences by government authorities, or the expropriation or nationalisation of any of Endeavour's property; risks associated with illegal and artisanal mining; environmental hazards; and risks associated with new diseases, epidemics and pandemics. Although Endeavour has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Please refer to Endeavour's most recent Annual Information Form filed under its profile at for further information respecting the risks affecting Endeavour and its business. The declaration and payment of future dividends and the amount of any such dividends will be subject to the determination of the Board of Directors, in its sole and absolute discretion, taking into account, among other things, economic conditions, business performance, financial condition, growth plans, expected capital requirements, compliance with the Company's constating documents, all applicable laws, including the rules and policies of any applicable stock exchange, as well as any contractual restrictions on such dividends, including any agreements entered into with lenders to the Company, and any other factors that the Board of Directors deems appropriate at the relevant time. There can be no assurance that any dividends will be paid at the intended rate or at all in the future. NON-GAAP MEASURES Some of the indicators used by Endeavour in this press release represent non-IFRS financial measures, including 'all-in margin', 'all-in sustaining cost', 'net cash / net debt', 'EBITDA', 'adjusted EBITDA', 'net cash / net debt to adjusted EBITDA ratio', 'cash flow from continuing operations', 'total cash cost per ounce', 'sustaining and non-sustaining capital', 'net earnings', 'adjusted net earnings', 'free cash flow', 'operating cash flow per share', 'free cash flow per share', and 'return on capital employed'. These measures are presented as they can provide useful information to assist investors with their evaluation of the pro forma performance. Since the non-IFRS performance measures listed herein do not have any standardised definition prescribed by IFRS, they may not be comparable to similar measures presented by other companies. Accordingly, they are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Please refer to the non-GAAP measures section in this press release and in the Company's most recently filed Management Report for a reconciliation of the non-IFRS financial measures used in this press release. Corporate Office: 5 Young St, Kensington, London W8 5EH, UK Attachments
Business Upturn
2 days ago
- Business
- Business Upturn
EssilorLuxottica: Publication of the 2025 Interim Financial Report
By GlobeNewswire Published on July 29, 2025, 21:30 IST Publication of the 2025 Interim Financial Report Paris, France (29 July 2025 – 6:30 pm) – The Board of Directors of EssilorLuxottica met on July 28, 2025 to approve the condensed consolidated interim financial statements for the six-month period ended June 30, 2025. EssilorLuxottica's 2025 Interim Financial Report has been published today. The Interim Financial Report comprises the First-half 2025 Management Report, the Condensed Consolidated Interim Financial Statements, the Statutory Auditors' Review Report on the Interim Financial Information and the Statement by the Person Responsible for the 2025 Interim Financial Report. The Interim Financial Report can be downloaded from EssilorLuxottica's website, under Investors – Financial Publications. Attachment DOWNLOAD THE PRESS RELEASE Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Wire
02-07-2025
- Business
- Business Wire
IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million
EVRY, France--(BUSINESS WIRE)--Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories, announces today its unaudited sales for the first half of 2024. Sales for the first half came to €2,540K, down 34% compared with the first half of 2024 on a like-for-like basis (excluding revenues from the SeqOIA platform), contrary to expectations of weak growth, comparable to that of 2024, as announced by the Company in its press release dated April 29, 2025, on its results for the 2024 financial year. This decline is the result of reduced activity of over 40% on the Institut Pasteur's Mutualized Microbiology platform, linked to the drop in epidemiological sequencing, as well as to the decline in projects carried out on the Evry genomics platform, down by around 31%. This decline is the result of delays in the start-up of two major projects, the first samples of which were received by the company in May, as well as a general slowdown in research projects for academic and hospital customers. The company believes that the second half of the year, with the acceleration of major projects (notably UMBRELLA) and improved funding conditions for public research, should enable the situation to improve from the third quarter onwards. As of June 30 th, available cash, including the remainder on the loan granted to the parent company OncoDNA and repaid over the course of 2025, stood at €2.1m. The company used up €0.9m of cash in the first half of 2025, and at this rate may not have enough cash to ensure its financing for the next 12 months. In this context, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the Company is not maintaining its revenue growth forecasts for 2025. Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: "The first half of the year has been extremely difficult, with both a sharp drop in academic and hospital research projects, linked to a reduction in public research financing, as well as a reduction in the budgets of several biotech companies in a sector affected by the general economic climate. Despite several successes such as the UMBRELLA project, whose operational launch was announced last month, IntegraGen needs to find new sources of funding to be able to ensure the continuity of its operations." Investors are invited to carefully read section 4.2 of the 2024 Management Report on 'Principal risks and uncertainties facing the Company'. Financial results for the first half of 2025 will be published in October. ABOUT INTEGRAGEN IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 40 employees and generated €8.5 million of turnover in 2024. Based in France, IntegraGen is part of the Belgian OncoDNA group present in Spain, UK, Germany and works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).
Politico
30-06-2025
- Climate
- Politico
Strained city EMS workforce feels the heat
Beat Memo A scorching heat wave last week is shining a spotlight on New York City's strained emergency medical response system. FDNY EMS Local 2507, the union for thousands of emergency medical technicians and paramedics, responded to over 20,000 medical emergencies over the sweltering four-day span. On Primary Day, the number of medical emergency calls was 20 percent higher than average, according to the union. City Health Department data shows that emergency department visits for heat-related illnesses peaked Wednesday at 141, while 112 New Yorkers showed up at hospitals the day before. The heightened demand for emergency medical responses meant some calls had to be placed on hold, while others waited up to three hours for an ambulance to arrive, union president Oren Barzilay said. 'Every day, FDNY EMS members are struggling to keep up with exceedingly high call volumes with an underappreciated and underinvested in workforce,' Barzilay said in a statement. The Fire Department told one news outlet that it responded to about 1,000 more calls per day than usual, noting that calls were prioritized so the neediest New Yorkers got help as soon as possible. Each summer, more than 500 people die prematurely because of hot weather in New York City, according to the city Health Department — and summers are getting hotter because of climate change. And that's only exacerbating retention issues among the city's EMS workforce, which has gone without a union contract for three years, Barzilay said. Emergency response times have risen in recent years due to a lack of emergency medical technicians and paramedics as well as a smaller pipeline of potential recruits, the Mayor's Management Report found in January 2025. 'Heat waves like this only exacerbate this fundamental issue,' he said in a statement. 'It's why there is such a massive burnout and stress among our membership, who are providing lifesaving medical care and transport each day in neighborhoods across our city.' IN OTHER NEWS: — Gov. Kathy Hochul signed legislation Friday that authorizes certain health care professionals licensed outside New York to treat participants in specific sporting events: the Ironman Lake Placid 2025 or an event sanctioned by the New York Road Runners. 'With world-class athletes traveling and competing across the state, New York wants to ensure they have the best care,' Hochul said in a statement. 'This legislation not only provides more opportunities for health care professionals, but it also allows athletes to have top-of-the-line care during their events.' — Northwell's Center for Gun Violence Prevention received $200,000 in gifts to expand research into the root causes of gun violence and to support development of a national toolkit for health systems to implement gun violence prevention initiatives. ON THE AGENDA: — Tuesday, 10:15 a.m. to 3:15 p.m. The Public Health and Health Planning Council's health planning committee will convene. MAKING ROUNDS: — Andrew T. Pickens was appointed executive director of western region hospitals for the Westchester Medical Center Health Network. GOT TIPS? Send story ideas and feedback to Maya Kaufman at mkaufman@ and Katelyn Cordero at kcordero@ Want to receive this newsletter every weekday? Subscribe to POLITICO Pro. You'll also receive daily policy news and other intelligence you need to act on the day's biggest stories. Odds and Ends NOW WE KNOW — Some cost-conscious Americans are making their own weight-loss drugs. TODAY'S TIP — How to protect yourself from ticks. STUDY THIS — Black and Hispanic patients with opioid use disorder were 'significantly less likely' to receive the medication buprenorphine, especially if they had commercial insurance, researchers found. What We're Reading — U.S. charges 11 in Russia-based scheme to bilk Medicare of $10.6 billion. (New York Times) — Too sick to work, some Americans worry Trump's bill will strip their health insurance. (KFF Health News) — People whose lives were permanently altered by disease send a warning as vaccine opposition grows. (AP) Around POLITICO — Via POLITICO's Erin Schumaker: RFK Jr. is bringing psychedelics to the Republican Party. — House GOP moderates dig in against Senate Medicaid cuts, Meredith Lee Hill and Nicholas Wu report. MISSED A ROUNDUP? Get caught up on the New York Health Care Newsletter.
Business Upturn
04-06-2025
- Business
- Business Upturn
EPSO-G announces audited Sustainability Performance Report for 2024
EPSO-G (company code: 302826889, registered office address Laisvės pr. 10, Vilnius, Lithuania) (hereinafter – the Group) announces the 2024 Sustainability Performance Report (the Performance Report), including an Independent Limited Assurance Report. The Independent Limited Assurance of the Performance Report has been carried out by PricewaterhouseCoopers. EPSO-G issued a EUR 75 million sustainability-linked bond ISIN LT0000406530 (hereinafter – the Bond prospectus) on 7 June 2022 (EUR 75,000,000 3.117 per cent. Senior Unsecured Sustainability-Linked Notes due 2027). Under the terms of the Bond, EPSO-G committed to achieving sustainability performance target (SPT1) to reduce its Scope 1 and Scope 2 GHG emissions (tCO 2 e) by 30% by 2026, compared to the 2019 baseline and SPT2 – ensure that the amount of energy not supplied (hereinafter – ENS) does not exceed 136.255 MWh in the period 2022-2026. PricewaterhouseCoopers has assessed the calculation and disclosure of Scope 1 and Scope 2 GHG emissions, and ENS indicator. The audit firm confirmed in an independent limited assurance report that the EPSO-G Group has calculated the two key performance indicators for 2024 in compliance with the criteria for disclosure of the sustainability indicators. The Performance Report provides the latest information on the progress of the Group's key sustainability-linked performance targets and its indicators in the implementation of both the 2022 EPSO-G Sustainability-linked Finance Framework and the commitments made by EPSO-G under the Bond prospectus. This Performance Report should be read in conjunction with the EPSO-G 2024 consolidated management report (hereinafter – Management Report), which contains information relating to sustainability and other significant events affecting the Group. The Management Report is presented together with the independent auditor's report on the audit of the separate and consolidated financial statements and the independent practitioner's limited assurance report on the EPSO-G consolidated sustainability statement for the year ended December 31, 2024. The EPSO-G group of companies consists of the holding company EPSO-G and its five direct subsidiaries Amber Grid, Baltpool, Energy Cells, Litgrid and Tetas. EPSO-G and its Group companies also hold shares in Rheinmetall Defence Lietuva, GET Baltic, Baltic RCC OÜ and TSO Holding AS. The rights and obligations of the sole shareholder of EPSO-G are exercised by the Ministry of Energy of the Republic of Lithuania. For more informationGediminas Petrauskas, Communications Partner at EPSO-G Tel. +370 610 63306, e-mail [email protected]
